華潤醫藥(03320.HK)累計增持華潤博雅生物股份達1%並擬繼續增持
格隆匯12月18日丨華潤醫藥(03320.HK)公吿,於2024年11月8日至2024年12月18日期間,公司全資附屬公司華潤醫藥控股有限公司)("華潤醫藥控股")透過深圳證券交易所交易系統的集中競價交易累計收購華潤博雅生物製藥集團股份有限公司("華潤博雅生物")額外5,042,400股股份(佔華潤博雅生物股本總額的1.00%)。
華潤博雅生物為一家於中華人民共和國註冊成立的公司。華潤博雅生物的股份於深圳證券交易所上市。截至本公吿日期及於上述增持股份後,公司透過華潤醫藥控股間接持有華潤博雅生物總股本約30.28%及總股本約41.59%表決權。華潤博雅生物作為公司附屬公司入賬。
華潤醫藥控股擬於自2024年11月8日起6個月內,通過適用證券法規允許的方式(包括但不限於集中競價交易及大宗交易)進一步增持華潤博雅生物股份。公司認為增持計劃體現華潤醫藥控股對華潤博雅生物價值的認可並對其持續穩定發展抱有信心,且有望提振投資者信心,切實維護投資者利益,並進一步促進華潤博雅生物的持續穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.